1
Orphan Designations
0 approved, 1 designated
1
FDA Approvals
Latest: RAPIBLYK (2024)
3
Active Trials
200 recruiting
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
AOP Orphan Pharmaceuticals GmbH is a company with 1 orphan drug designation across 2 rare diseases, including 1 FDA-approved therapy. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Huntington disease | selisistat | Des.TrialAppr. |
| pulmonary hypertension | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio